Blog

Feds Purchase Agreement for Lilly’s bamlanivimab (LY-CoV555) Is Another Milestone for Antibody Drugs for COVID-19

Patients will have no out-of-pocket costs for the medication; potential for purchase of an additional 650,000 vials The purchase agreement announced today between the Federal Government’s Operation Warp Speed and Eli Lilly for bamlanivimab (LY-CoV555) marks another major milestone and vote of confidence for antibody drugs and therapeutics to turn the tide in the war on […]

Regeneron Publishes Phase 2/3 Trial Data Demonstrates that REGN COV-2 is a Game Changer for high risk adults with mild-to-moderate COVID-19

October 29, 2020. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Wednesday positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, telemedicine visits, etc.). The randomized, double-blind trial is measuring the effect of adding REGN-COV2 to […]

What Does the Eli Lilly ACTIV-3 Trial Results Mean for Antibody Treatments? Prevention and Protection Should Be the Focus.

In an update on Monday (October 26), Eli Lilly stated that the pause of the ACTIV-3 trial was made permanent. The reason was not a safety issue with the antibody treatment – i.e. unanticipated side effect – but rather that it was ineffective on patients already hospitalized with advanced COVID-19. As noted by Dr. Eric Topol, a […]

Be a Hero: Volunteer for a Clinical Trial. It Could Save Your Life Too.

Over the last 9 months, we have seen truly heroic efforts of leaders in science, industry and government working in public-private partnerships and global collaboration to innovate and accelerate the development of effective vaccines and treatments for COVID-19 on a time scale previously unimaginable. This should give us all encouragement that despite the political disfunction […]

Scroll to top